FIGHT-302 is currently ongoing, which is an open-label, randomized, active-control, phase 3 study evaluating first-line pemigatinib versus gemcitabine plus cisplatin in the treatment of CCA with FGFR2 rearrangement [59]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.